Navigation Links
InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
Date:2/25/2008

LOS ALTOS, Calif., Feb. 25 /PRNewswire/ -- InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease, announced today that it has initiated a Phase 2b study in diabetic patients with its lead product candidate INT131, a non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator). INT131 was the result of an extensive molecular design effort to address the product profile deficiencies of current TZD therapy, which while efficacious present problematic safety concerns. INT131 was selected specifically for its ability to reduce characteristic TZD adverse effects while retaining powerful PPAR anti-diabetic efficacy. This placebo controlled, double-blind, Phase 2b study includes multiple doses of orally administered INT131 once daily, and Actos(R) (pioglitazone) as an active comparator.

"INT131 has consistently demonstrated potent and selective PPAR-gamma modulation through each phase of development including recently completed primate safety studies, wherein an absence of recognized TZD adverse effects such as edema offers a genuine breakthrough for this target," said Linda Slanec Higgins, PhD, InteKrin's Chief Scientific Officer. "Preclinical safety multiples with INT131 are far greater than those seen with the currently marketed, first generation TZD full agonists."

"From a clinical perspective, insulin resistance is a key etiological feature in the onset and subsequent progression of Type 2 Diabetes, and it remains inadequately addressed by current therapies. INT131 has been demonstrated to be a potent and efficacious insulin sensitizer in humans and offers the opportunity for disease modification without the edema and weight gain of current TZD therapies," said Alex DePaoli, MD, InteKrin's Chief Medical Officer. "The initiation of this robust Phase 2b study represents an imp
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
2. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
5. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
6. ImaRx Therapeutics Transitions Business Strategy
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... Toronto (PRWEB) September 23, 2014 ... the Canadian specialty market, is now providing U.S. ... its new 160,000-square-foot distribution center coupled with its ... Canadian healthcare industry has historically been difficult for ... to government regulation complexities. As a result of ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 The print ... of the Metro, with a circulation of approximately 327,720 ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... features an exclusive interview with Michael Landsberg, host of ...
(Date:9/23/2014)... 2014 Antibiotics revolutionized health care in the ... killed thousands of people. But bacteria are also ... bacteria are popping up more frequently. This week,s ... of new antibiotics and discusses the prospects for ... Why should you finish your pills if you ...
(Date:9/23/2014)... to what is often assumed about single parents, particularly ... The Kinsey Institute has found that single parents of ... as often as singles without children -- and more ... study, "Dating and Sexual Behavior Among Single Parents of ... in the Journal of Sex Research prior ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 On September 23, ... Keith Simmons for an episode. Simmons is the founder of ... believed the audience would like to know. At the start ... the idea to start this magazine?” Simmons replied by saying, ... sales person. In 2005, I quit that and decided to ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... Society for Gastrointestinal Endoscopy (ASGE) and the American Society ... new white paper on the potential role of endoscopic ... like Type 2 diabetes. The white paper ... in both GIE: Gastrointestinal Endoscopy, the peer-reviewed ...
... standards for teaching women and clinicians how to perform ... to detect lumps earlier and save lives. Widely-publicized ... of cancer. The Center for Disease Control reports that ... most common cancer among American females. The National ...
... keep blood vessels open to treat heart disease are ... the Journal of Interventional Cardiology . A case ... of the Detroit Medical Center Cardiovascular Institute, and her ... after the recently marketed Ion stent (Boston Scientific, Natick, ...
... of organic horticultural crops frequently fall below those of ... of organic production. Researchers recently studied the growth and ... with vermicompost and compared the results with plants grown ... area is needed to provide a base of information ...
... has found that people are willing to pay up to 29.91 ... Researchers surveyed the public in the two major urban centres ... were willing to pay in council tax or rent/mortgage payments for ... willing to pay more for greener spaces with greater tree coverage. ...
... poisonous snakes, a group of researchers at the University of ... small black, yellow and red serpent called the Texas coral ... insights into chronic and acute pain and provides new ... combat pain. The venom contains a toxic mixture of ...
Cached Medicine News:Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 3Health News:Public willing to pay more for greener urban spaces 2Health News:Public willing to pay more for greener urban spaces 3Health News:Snake spills venomous secrets 2Health News:Snake spills venomous secrets 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
Medicine Products: